blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2019683

EP2019683 - ADMINISTRATION OF GROWTH FACTORS FOR THE TREATMENT OF CNS DISORDERS [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  01.07.2022
Database last updated on 23.04.2024
FormerThe patent has been granted
Status updated on  11.11.2016
FormerGrant of patent is intended
Status updated on  04.11.2016
Most recent event   Tooltip01.07.2022Patent maintained (B2 publication)published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
The Regents of the University of California
1111 Franklin Street, 12th Floor
Oakland, CA 94607 / US
[2016/50]
Former [2009/06]For all designated states
The Regents of the University of California
1111 Franklin Street, 12th Floor
Oakland, CA 94607-5200 / US
Inventor(s)01 / BANKIEWICZ, Krystof, S.
5815 Balmoral Drive
Oakland, CA 94619 / US
 [2009/06]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2022/31]
Former [2016/50]Brasnett, Adrian Hugh, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Former [2009/06]Brasnett, Adrian Hugh, et al
Mewburn Ellis LLP 33 Gutter Lane London
EC2V 8AS / GB
Application number, filing date07761286.925.04.2007
[2009/06]
WO2007US67423
Priority number, dateUS20060795012P25.04.2006         Original published format: US 795012 P
[2009/06]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2007127803
Date:08.11.2007
Language:EN
[2007/45]
Type: A2 Application without search report 
No.:EP2019683
Date:04.02.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 08.11.2007 takes the place of the publication of the European patent application.
[2009/06]
Type: B1 Patent specification 
No.:EP2019683
Date:14.12.2016
Language:EN
[2016/50]
Type: B2 New European patent specification 
No.:EP2019683
Date:03.08.2022
Language:EN
[2022/31]
Search report(s)International search report - published on:US23.10.2008
(Supplementary) European search report - dispatched on:EP12.07.2010
ClassificationIPC:A61K9/00, A61K49/18, A61K33/24, A61K49/04, A61K51/12, A61K38/18, A61K48/00
[2016/21]
CPC:
A61K38/18 (EP,US); A61K33/242 (EP,US); A61K33/244 (EP,US);
A61K38/185 (EP,US); A61K48/0083 (EP,US); A61K49/0466 (EP,US);
A61K49/1812 (EP,US); A61K51/1234 (US); A61K9/0085 (EP,US);
A61P25/00 (EP); A61P25/08 (EP); A61P25/14 (EP);
A61P25/16 (EP); A61P25/18 (EP); A61P25/28 (EP);
A61P27/02 (EP); A61P3/04 (EP); A61P43/00 (EP);
A61P9/10 (EP); C12N2750/14143 (EP,US) (-)
C-Set:
A61K33/24, A61K2300/00 (EP,US)
Former IPC [2010/32]A61K39/00, A61K38/18
Former IPC [2009/06]A61K39/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/50]
Former [2009/06]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:VERABREICHUNG VON WACHSTUMSFAKTOREN ZUR BEHANDLUNG VON ZNS-ERKRANKUNGEN[2009/06]
English:ADMINISTRATION OF GROWTH FACTORS FOR THE TREATMENT OF CNS DISORDERS[2009/06]
French:ADMINISTRATION DE FACTEURS DE CROISSANCE POUR TRAITER DES TROUBLES DU SNC[2009/06]
Entry into regional phase25.11.2008National basic fee paid 
25.11.2008Search fee paid 
25.11.2008Designation fee(s) paid 
25.11.2008Examination fee paid 
Examination procedure25.11.2008Examination requested  [2009/06]
08.02.2011Amendment by applicant (claims and/or description)
28.03.2013Despatch of a communication from the examining division (Time limit: M06)
27.08.2013Reply to a communication from the examining division
30.10.2014Despatch of a communication from the examining division (Time limit: M06)
11.05.2015Reply to a communication from the examining division
28.01.2016Despatch of a communication from the examining division (Time limit: M04)
14.04.2016Reply to a communication from the examining division
13.05.2016Communication of intention to grant the patent
22.09.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
22.09.2016Fee for grant paid
22.09.2016Fee for publishing/printing paid
04.11.2016Information about intention to grant a patent
04.11.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.03.2013
Opposition(s)Opponent(s)01  13.09.2017  19.09.2017  ADMISSIBLE
Herantis Pharma Oyj
Bertel Jungin aukio 1
02600 Espoo / FI
Opponent's representative
Laine IP Oy
Porkkalankatu 24
00180 Helsinki / FI
 [2021/13]
Former [2019/52]
Opponent(s)01  13.09.2017  19.09.2017  ADMISSIBLE
Herantis Pharma Oyj
Viikinkaari 4
00790 Helsinki / FI
Opponent's representative
Seppo Laine Oy
Porkkalankatu 24
00180 Helsinki / FI
Former [2017/43]
Opponent(s)01  13.09.2017  19.09.2017  ADMISSIBLE
Herantis Pharma Oyj
Viikinkaari 4
00790 Helsinki / FI
Opponent's representative
Seppo Laine Oy
Itämerenkatu 3 A
00180 Helsinki / FI
23.10.2017Invitation to proprietor to file observations on the notice of opposition
01.03.2018Reply of patent proprietor to notice(s) of opposition
05.03.2019Date of oral proceedings
12.04.2019Despatch of minutes of oral proceedings
15.04.2019Despatch of interlocutory decision in opposition
24.01.2022Legal effect of interlocutory decision in opposition
17.03.2022Despatch of communication that the patent will be maintained as amended
23.06.2022Fee for printing new specification paid
Appeal following opposition24.06.2019Appeal received No.  T1910/19
23.08.2019Statement of grounds filed
24.01.2022Result of appeal procedure: appeal of the opponent withdrawn
24.06.2019Appeal received No.  T1910/19
22.08.2019Statement of grounds filed
22.12.2020Invitation to file observations in an appeal (Time limit: M02) [2020/52]
24.01.2022Result of appeal procedure: appeal of the opponent withdrawn
Fees paidRenewal fee
29.04.2009Renewal fee patent year 03
26.04.2010Renewal fee patent year 04
25.04.2011Renewal fee patent year 05
28.03.2012Renewal fee patent year 06
29.04.2013Renewal fee patent year 07
28.04.2014Renewal fee patent year 08
27.04.2015Renewal fee patent year 09
27.04.2016Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY14.12.2016
EE14.12.2016
LT14.12.2016
LV14.12.2016
MC14.12.2016
IS14.04.2017
MT25.04.2017
[2019/46]
Former [2018/43]EE14.12.2016
LT14.12.2016
LV14.12.2016
MC14.12.2016
IS14.04.2017
MT25.04.2017
Former [2018/06]EE14.12.2016
LT14.12.2016
LV14.12.2016
MC14.12.2016
IS14.04.2017
Former [2017/43]EE14.12.2016
LT14.12.2016
LV14.12.2016
IS14.04.2017
Former [2017/28]LT14.12.2016
LV14.12.2016
Former [2017/12]LV14.12.2016
Documents cited:Search[A]WO2004075720  (NORTH BRISTOL N H S TRUST [GB], et al) [A] 1-15 * the whole document *;
 [X]WO2005120548  (STREATFIELD GILL STEVEN [GB]) [X] 1,2,11 * page 33, line 14 - page 34, line 14 * * page 38, line 16 - line 26 * * claim - *;
 [XP]WO2006044115  (AMGEN INC [US], et al) [XP] 1,2,6,11-15 * page 28; example 2; claim - *;
 [X]  - HAMILTON J F ET AL, "Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin", EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US LNKD- DOI:10.1006/EXNR.2000.7571, (20010301), vol. 168, no. 1, ISSN 0014-4886, pages 155 - 161, XP002409643 [X] 1,2,4,11 * the whole document *

DOI:   http://dx.doi.org/10.1006/exnr.2000.7571
 [X]  - KIRIK DENIZ ET AL, "Localized striatal delivery of GDNF as a treatment for Parkinson disease", NATURE NEUROSCIENCE, NATURE AMERICA, INC, US LNKD- DOI:10.1038/NN1175, (20040201), vol. 7, no. 2, ISSN 1097-6256, pages 105 - 110, XP002343709 [X] 1,11-14 * the whole document * * page 108, column l * * page 109, column l *

DOI:   http://dx.doi.org/10.1038/nn1175
 [A]  - GILL S S ET AL, "Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US LNKD- DOI:10.1038/NM850, (20030501), vol. 9, no. 5, ISSN 1078-8956, pages 589 - 595, XP002343708 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/nm850
 [A]  - MASWOOD N ET AL, "Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US LNKD- DOI:10.1016/S0197-4580(02)00022-2, (20020101), vol. 23, no. 5, ISSN 0197-4580, pages 881 - 889, XP002293324 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0197-4580(02)00022-2
 [A]  - BRUNDIN PATRIK, "GDNF treatment in Parkinson's disease: Time for controlled clinical trials?", BRAIN, OXFORD UNIVERSITY PRESS, OXFORD, GB LNKD- DOI:10.1093/BRAIN/AWF217, (20021001), vol. 125, no. 10, ISSN 0006-8950, pages 2149 - 2151, XP002293327 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1093/brain/awf217
 [A]  - SLEVIN JOHN T ET AL, "Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor", JOURNAL OF NEUROSURGERY, AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS, US LNKD- DOI:10.3171/JNS.2005.102.2.0216, (20050201), vol. 102, no. 2, ISSN 0022-3085, pages 216 - 222, XP002427990 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.3171/jns.2005.102.2.0216
 [A]  - GRONDIN R ET AL, "CHRONIC, CONTROLLED GDNF INFUSION PROMOTES STRUCTURAL AND FUNCTIONAL RECOVERY IN ADVANCED PARKINSONIAN MONKEYS", BRAIN, OXFORD UNIVERSITY PRESS, OXFORD, GB LNKD- DOI:10.1093/BRAIN/AWF234, (20021001), vol. 125, no. PART 10, ISSN 0006-8950, pages 2191 - 2201, XP009035486 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1093/brain/awf234
International search[X]US2002114780  (BANKIEWICZ KRYS [US], et al) [X] 1 * , entire document. *;
 [XE]US7371225  (OLDFIELD EDWARD H [US], et al) [XE] 2-5, 9, 10 and 15-25* , entire document. *
by applicantUS5720720
 US6042579
 US2002114780
 US2006073101
    - SAITO ET AL., EXP. NEUROL., (2005), vol. 196, pages 3891 - 389
    - KRAUZE ET AL., EXP. NEUROL., (2005), vol. 196, pages 104 - 111
    - KRAUZE ET AL., BRAIN RES. BRAIN RES. PROTOCOL., (2005), vol. 16, pages 20 - 26
    - CUNNINGHAM; WELLS, SCIENCE, (1989), vol. 244, pages 1081 - 1085
    - HADACZEK ET AL., HUMAN GENE THERAPY, (2006), vol. 17, pages 1 - 12
    - SCIENCE, (1993), vol. 260, pages 1130 - 1132
    - KRIEGLSTEIN ET AL., EMBO J., (1995), vol. 14, pages 736 - 742
    - POULSEN ET AL., NEURON, (1994), vol. 13, pages 1245 - 1252
    - LIN ET AL., SCIENCE, (1993), vol. 260, pages 1130 - 1132
    - HUDSON ET AL., BRAIN RES. BULL, (1995), vol. 36, pages 425 - 432
    - BECK ET AL., NATURE, (1995), vol. 373, pages 339 - 341
    - TOMAC ET AL., NATURE, (1995), vol. 373, pages 335 - 339
    - HOFFER ET AL., NEUROSCI. LETT, (1994), vol. 182, pages 107 - 111
    - OPPENHEIM ET AL., NATURE, (1995), vol. 373, pages 344 - 346
    - ZURN ET AL., NEUROREPORT, (1994), vol. 6, pages 113 - 118
    - YAN ET AL., NATURE, (1995), vol. 373, pages 341 - 344
    - HENDERSON ET AL., SCIENCE, (1994), vol. 266, pages 1062 - 1064
    - SARIOLA ET AL., J. CELL SCI., (20031001), vol. 116, pages 3855 - 62
    - VENERO ET AL., NEUROREPORT, (1993), vol. 4, pages 959 - 962
    - HEFTI, J. NEUROBIOL, (1994), vol. 25, pages 1418 - 1435
    - OLSON, NEUROCHEM, (1994), pages 1 - 3
    - BATCHELOR ET AL., J. COMP. NEUROL., (1989), vol. 284, pages 187 - 204
    - KISS ET AL., NEUROSCI., (1988), vol. 27, pages 731 - 748
    - WOOLF ET AL., NEUROSCI, (1989), vol. 30, pages 143 - 152
    - SELKOE, NEURON, (1991), vol. 6, pages 487 - 498
    - PETTY ET AL., ANN. AUG, (1994), vol. 36, pages 244 - 246
    - ESLAMBOLI, REV. NEUROSCI, (2005), vol. 16, no. 4, pages 303 - 10
    - KORDOWER ET AL., ANN. NEUROL., (1999), vol. 46, pages 419 - 424
    - GILL ET AL., NAT. MED., (2003), vol. 9, pages 5899 - 595
    - PATEL ET AL., ANN. NEUROL., (2005), vol. 57, pages 298 - 302
    - LANG ET AL., ANN. NEUROL., (2006), vol. 59, pages 459 - 466
    - ESLAMBOLI, REV. NEUROSCI., (2005), vol. 16, no. 4, pages 303 - 10
    - KRAUZE ET AL., EXP NEUROL., (200511), vol. 196, no. 1, pages 104 - 11
OppositionUS2002114780
    - Christian WINKLER et al., "Short-Term GDNF Treatment Provides Long-Term Rescue of Lesioned Nigral Dopaminergic Neurons in a Rat Model of Parkinson's Disease", The Journal of Neuroscience, (19961115), vol. 16, no. 22, pages 7206 - 7215, XP055419561

DOI:   http://dx.doi.org/10.1523/JNEUROSCI.16-22-07206.1996
    - LINDAHL et al., "Unconventional neurotrophic factors CDNF and MANF: Structure, physiological functions and therapeutic potential", Neurobiology of Disease, (20170000), vol. 97, pages 90 - 102, XP029839509

DOI:   http://dx.doi.org/10.1016/j.nbd.2016.07.009
    - Christian WINKLER et al., "Short-Term GDNF Treatment Provides Long-Term Rescue of Lesioned Nigral Dopaminergic Neurons in a Rat Model of Parkinson's Disease", The Journal of Neuroscience, (19961115), vol. 16, no. 22, pages 7206 - 7215
    - LINDAHL et al., "Unconventional neurotrophic factors CDNF and MANF: Structure, physiological functions and therapeutic potential", Neurobiology of Disease, (20170000), vol. 97, pages 90 - 102
    - Bobo et al, 1994, PNAS 91:2076-80
    - Morrison et al, 1994, Am.J.Physiol. 266: R292-R305
    - Allard et al, 2009, Biomaterials 30: 2302-18
    - Schober, Cell Tissue Res., 2004, 318: 215-224
    - Grodin et al, 2002, Brain, 125: 2119-2201
    - Gill et al. 2003. Nature Medicine. 9(5): 589-95
    - Slevin et al, 2005, J Neurosurg 102: 216-22
    - Lang et al, 2006, Ann Neurol 59: 459-66
    - Patel and Gill, 2007, Acta Neurochir Suppl 97(2): 135-154
    - Morrison et al. 2007, J Neurosurg 107: 74-83
    - Salvatore et al, 2006, Exp Neurol 202: 497-505
    - Sherer et al, 2006, Movement Disorders 21(2): 136-41
    - Hadaczek et al, 2010, Neuropharmacology 58: 1114-21
    - Taylor et al, 2013, PLOS One 8(3):e56186, p. 1 -9
    - http://www.medlink.com/article/neurotrophic-factors
    - Argente-Arizon et al, 2015, Fronteers in Endocrinology 6, article 42, p.1-15
    - PubMed abstract of Gold, 2000, Expert Opin Investig Drugs 9(10): 2331-42
    - McGeachie et al, 1997, Australian Dental Journal 42(6):375-80
    - Guo et al, 2001, Ann Neurol 50: 6-16
    - Poulter et al, 2004, Neuroscience 128: 1-6
    - Huttunen, H and M Saarma (2019) Cell transplantation 28(4):349-366
    - Mocchetti, I. (2005) Cell. Mol. Life Sci. 62:2283-94
    - Fusco, M. et al (1993) Ann. NY. Acad. Sci 695:314-7
    - Lim, S T et al (2011) Neuropharmacology 60:1160-7
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.